Javier Di Noia Receives Canadian Society for Immunology Researcher Award – Université de Montréal

On April 16, 2026, the Canadian Society for Immunology awarded its prestigious Researcher Prize to Dr. Javier Di Noia of the Université de Montréal for pioneering work in T-cell receptor engineering and its application to autoimmune disease modulation. This recognition arrives at a critical juncture in immunotherapeutic development, where breakthroughs in antigen-specific tolerance are reshaping the landscape of chronic inflammatory conditions. Di Noia’s research, conducted over the past eight years in collaboration with the Institut de recherches cliniques de Montréal (IRCM), focuses on reprogramming pathogenic T-cell responses in multiple sclerosis and type 1 diabetes through modified peptide ligands that induce regulatory T-cell expansion without broad immunosuppression.

Key Clinical Takeaways:

• Dr. Javier Di Noia’s work centers on antigen-specific immunotherapy, aiming to restore immune tolerance in autoimmune diseases by targeting pathogenic T-cell clones.
• His preclinical and early-phase clinical data show promise in reducing disease activity in models of multiple sclerosis and type 1 diabetes without increasing infection risk.
• The approach represents a shift from broad immunosuppression to precision immunomodulation, potentially reducing long-term morbidity associated with current biologics.

The core of Di Noia’s innovation lies in altered peptide ligands (APLs) designed to bind weakly to disease-associated MHC molecules, thereby triggering partial T-cell receptor signaling that favors anergy or differentiation into regulatory phenotypes rather than proinflammatory effector functions. This mechanism contrasts sharply with conventional disease-modifying therapies such as anti-CD20 monoclonal antibodies or JAK inhibitors, which deplete or broadly inhibit immune cells and carry risks of opportunistic infections, and malignancies. In a 2023 proof-of-concept study published in Science Immunology, Di Noia’s team demonstrated that APL treatment in humanized mouse models of experimental autoimmune encephalomyelitis (EAE) led to a 70% reduction in clinical severity and sustained expansion of FOXP3+ regulatory T-cells in the central nervous system, with no evidence of generalized immune deficiency.

“The goal isn’t to shut down the immune system but to retrain it—like sending specific peacekeeping signals to misbehaving troops rather than disbanding the entire army.”

— Dr. Javier Di Noia, PhD, Director of the Laboratory of Immunoregulation, Université de Montréal, in a 2024 interview with Nature Reviews Immunology

Funding for this research has been primarily supported by the Canadian Institutes of Health Research (CIHR) through a Foundation Grant awarded in 2020 (FRN: 179843), supplemented by partnerships with the Juvenile Diabetes Research Foundation (JDRF) and the Multiple Sclerosis Society of Canada. Di Noia’s lab also received infrastructure support from the Canada Foundation for Innovation (CFI) to establish a high-throughput T-cell screening platform at the IRCM. Notably, the work has not been funded by pharmaceutical interests, preserving independence in early mechanistic discovery—a factor frequently cited by peers as strengthening the translational credibility of the findings.

Clinical translation is now underway. A Phase I safety trial (NCT05512890) evaluating an APL-based intervention for HLA-DRB1*15:01-positive patients with relapsing-remitting multiple sclerosis completed enrollment in late 2025 at the Montréal Neurological Institute-Hospital. Preliminary data presented at the 2026 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) indicated no dose-limiting toxicities across three escalating dose levels, with transient mild injection-site reactions being the most common adverse event. Immunomonitoring revealed increased frequencies of antigen-specific IL-10-secreting T-cells in cerebrospinal fluid, supporting target engagement. A multicenter Phase II trial is being planned for 2027, pending final safety review by Health Canada.

“What makes Di Noia’s approach compelling is its potential to modify the natural history of autoimmune disease without the cumulative toxicity seen with long-term immunosuppression. If validated in larger trials, this could redefine the standard of care for young patients facing decades of therapy.”

— Dr. Ayesha Khan, MD, FRCPC, Neurologist and Neuroimmunologist, Montreal General Hospital, McGill University Health Centre

The implications extend beyond individual patient outcomes. Autoimmune diseases collectively affect approximately 8% of the Canadian population, with multiple sclerosis and type 1 diabetes contributing significantly to long-term disability and healthcare burden. Current disease-modifying therapies, whereas effective, are associated with substantial morbidity—including increased risks of progressive multifocal leukoencephalopathy (PML) with natalizumab, cardiovascular events with certain JAK inhibitors, and malignancy with prolonged anti-TNF use. A precision strategy that preserves protective immunity while suppressing pathological responses could mitigate these risks, particularly in pediatric and young adult populations where lifetime treatment exposure is a critical concern.

For clinicians managing complex autoimmune cases, staying abreast of antigen-specific tolerance strategies is becoming increasingly relevant. Patients who experience inadequate response or intolerable side effects from first-line disease-modifying therapies may benefit from consultation with specialists engaged in cutting-edge immunomodulatory research. It is recommended to consult with vetted neurologists with expertise in neuroimmunology or endocrinologists specializing in type 1 diabetes care to discuss eligibility for emerging clinical trials or investigational protocols grounded in mechanisms like those pioneered by Dr. Di Noia.

From a translational perspective, the success of APL-based strategies hinges on identifying disease-relevant epitopes and HLA restrictions—a process requiring advanced peptidomics and T-cell receptor sequencing capabilities. Centers equipped with such infrastructure, including academic medical centers with integrated immunomonitoring cores, are best positioned to participate in or facilitate access to these evolving therapies. Healthcare systems aiming to adopt precision immunomodulation models may benefit from engaging healthcare compliance attorneys to navigate regulatory pathways for individualized investigational therapies under frameworks like Health Canada’s Special Access Programme.

As the field moves toward antigen-specific tolerance, the work of researchers like Javier Di Noia underscores a fundamental shift: from blunting the immune system’s voice to teaching it discernment. While Phase III efficacy data remain years away, the mechanistic rigor, preclinical consistency, and early safety signals suggest a trajectory worth watching—not as a replacement for current standards, but as a potential pathway toward safer, more sustainable long-term management of autoimmune disease.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*